These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 27112532

  • 1. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus.
    Cohen S, Clowse M, Pardo P, Bhattacharya I, Menon S, Gourley I, Diehl A.
    Clin Ther; 2016 Jun; 38(6):1417-1434.e2. PubMed ID: 27112532
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study.
    Burge DJ, Bookbinder SA, Kivitz AJ, Fleischmann RM, Shu C, Bannink J.
    Clin Ther; 2008 Oct; 30(10):1806-16. PubMed ID: 19014836
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus.
    Witcher J, Fleischmann R, Chindalore VL, Hansen RJ, Hu L, Radtke D, Voelker J, Gomez E, McColm J.
    Br J Clin Pharmacol; 2016 May; 81(5):908-17. PubMed ID: 26648084
    [Abstract] [Full Text] [Related]

  • 4. Safety and Efficacy of SBI-087, a Subcutaneous Agent for B Cell Depletion, in Patients with Active Rheumatoid Arthritis: Results from a Phase II Randomized, Double-blind, Placebo-controlled Study.
    Damjanov N, Tlustochowicz M, Aelion J, Greenwald M, Diehl A, Bhattacharya I, Peeva E, Menon S, Gourley I.
    J Rheumatol; 2016 Dec; 43(12):2094-2100. PubMed ID: 27909139
    [Abstract] [Full Text] [Related]

  • 5. Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.
    Stohl W, Merrill JT, Looney RJ, Buyon J, Wallace DJ, Weisman MH, Ginzler EM, Cooke B, Holloway D, Kaliyaperumal A, Kuchimanchi KR, Cheah TC, Rasmussen E, Ferbas J, Belouski SS, Tsuji W, Zack DJ.
    Arthritis Res Ther; 2015 Aug 20; 17(1):215. PubMed ID: 26290435
    [Abstract] [Full Text] [Related]

  • 6. Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics.
    Kurrasch R, Brown JC, Chu M, Craigen J, Overend P, Patel B, Wolfe S, Chang DJ.
    J Rheumatol; 2013 Jul 20; 40(7):1089-96. PubMed ID: 23729801
    [Abstract] [Full Text] [Related]

  • 7. Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus.
    Reddy V, Cambridge G, Isenberg DA, Glennie MJ, Cragg MS, Leandro M.
    Arthritis Rheumatol; 2015 May 20; 67(8):2046-55. PubMed ID: 25916583
    [Abstract] [Full Text] [Related]

  • 8. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
    Vallerskog T, Heimbürger M, Gunnarsson I, Zhou W, Wahren-Herlenius M, Trollmo C, Malmström V.
    Arthritis Res Ther; 2006 May 20; 8(6):R167. PubMed ID: 17092341
    [Abstract] [Full Text] [Related]

  • 9. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F, Isenberg DA.
    Handb Exp Pharmacol; 2008 May 20; (181):163-81. PubMed ID: 18071946
    [Abstract] [Full Text] [Related]

  • 10. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
    Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF.
    Inflammopharmacology; 2015 Oct 20; 23(5):231-69. PubMed ID: 26246395
    [Abstract] [Full Text] [Related]

  • 11. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.
    Zhuang Y, Xu Z, Frederick B, de Vries DE, Ford JA, Keen M, Doyle MK, Petty KJ, Davis HM, Zhou H.
    Clin Ther; 2012 Jan 20; 34(1):77-90. PubMed ID: 22169051
    [Abstract] [Full Text] [Related]

  • 12. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial.
    Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC.
    Arthritis Res Ther; 2012 Jan 08; 14(1):R6. PubMed ID: 22225620
    [Abstract] [Full Text] [Related]

  • 13. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples.
    Reddy V, Klein C, Isenberg DA, Glennie MJ, Cambridge G, Cragg MS, Leandro MJ.
    Rheumatology (Oxford); 2017 Jul 01; 56(7):1227-1237. PubMed ID: 28407142
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.
    Mohamed MF, Camp HS, Jiang P, Padley RJ, Asatryan A, Othman AA.
    Clin Pharmacokinet; 2016 Dec 01; 55(12):1547-1558. PubMed ID: 27272171
    [Abstract] [Full Text] [Related]

  • 15. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
    Tanaka Y.
    Yakugaku Zasshi; 2009 Jun 01; 129(6):675-9. PubMed ID: 19483410
    [Abstract] [Full Text] [Related]

  • 16. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW, Roth D, Gordon D, Struemper H.
    Lupus; 2016 Nov 01; 25(13):1448-1455. PubMed ID: 27072354
    [Abstract] [Full Text] [Related]

  • 17. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.
    Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D.
    Arthritis Rheum; 2007 Dec 01; 56(12):4142-50. PubMed ID: 18050206
    [Abstract] [Full Text] [Related]

  • 18. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
    Eisenberg R, Albert D.
    Nat Clin Pract Rheumatol; 2006 Jan 01; 2(1):20-7. PubMed ID: 16932648
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus.
    Yao Z, Loggia L, Fink D, Chevrier M, Marciniak S, Sharma A, Xu Z.
    Clin Drug Investig; 2020 Dec 01; 40(12):1127-1136. PubMed ID: 33085033
    [Abstract] [Full Text] [Related]

  • 20. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study.
    Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, Mircetic V, Rischmueller M, Nasonov E, Shmidt E, Emery P, Munafo A.
    Arthritis Rheum; 2008 Jan 01; 58(1):61-72. PubMed ID: 18163485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.